![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1601612
¼¼°èÀÇ ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå - ±Ô¸ð, Á¡À¯À², ¿¹Ãø, µ¿Ç⠺м® : Á¦°ø Á¦Ç°º°(¶óÀ̺귯¸® Áغñ, DNA ÃßÃâ), ½ÃÄö½Ì À¯Çüº°(´ë±Ô¸ð, ¼Ò±Ô¸ð, À§»ó), ±â¼úº°(SBS, SMRT, ³ª³ëÆ÷¾î, ³ª³ëº¼), ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(-2031³â)Whole Genome Sequencing Market Size, Share, Forecast, & Trends Analysis by Offering (Library Preparation, DNA Extraction) Sequencing Type (Large, Small, Phased), Technology (SBS, SMRT, Nanopore, Nanoball) Application, End User - Global Forecast to 2031 |
¼¼°èÀÇ ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀåÀº 2024³âºÎÅÍ 2031³â±îÁöÀÇ CAGRÀÌ 15.2%·Î, 2031³â±îÁö 71¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
±¤¹üÀ§ÇÑ 2Â÷ Á¶»ç¿Í 1Â÷ Á¶»ç, ½ÃÀå ½Ã³ª¸®¿ÀÀÇ »ó¼¼ÇÑ ºÐ¼®À» °ÅÃÄ, º» º¸°í¼´Â ÁÖ¿ä »ê¾÷ ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, °úÁ¦, ±âȸÀÇ ºÐ¼®À¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ºñ¿ë ÀúÇÏ, ¾Ï ±×¸®°í À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, Áúº´ Áø´Ü ¹× Á¤¹Ð ÀÇ·á¿¡¼ÀÇ ÀüÀå À¯Àüü ½ÃÄö½ÌÀÇ ÀÌ¿ë È®´ë, ÀǾàǰ ¿¬±¸ °³¹ßºñ Áõ°¡, ÀüÀå À¯Àüü ½ÃÄö½Ì¿¡ °üÇÑ ±ÔÁ¦ ¹× »óȯ ½Ã³ª¸®¿ÀÀÇ °³¼±, ÀÇ·áºñ Áõ°¡, ¿¬±¸ Ȱµ¿¿¡ ÀÚ±Ý Á¦°ø Áõ°¡, Áúº´ÀÇ Á¶±â ¹ß°ß ¹× ¿¹¹æ¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡, ½ÃÄö½Ì Á¦Ç°ÀÇ ±â¼úÀû Áøº¸, ÀÓ»ó ¹× ¿¬±¸ ¿ëµµ¿¡¼ ½ÃÄö½ÌÀÇ ÀÌ¿ëÀ» ÃËÁøÇÏ´Â Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù. ½ÃÄö½Ì ¼Ò¸ðǰÀÇ ºñ¿ëÀÌ ³ô°í, Á¤¹ÐÀǷḦ À§ÇÑ ±àÁ¤ÀûÀÌ°í ½Ç¿ëÀûÀÎ µ¹¿¬º¯À̸¦ È®ÀÎÇÒ °¡´É¼ºÀÌ ³·´Ù´Â °Í, ÀüÀå À¯Àüü ½ÃÄö½Ì ±â¹Ý Áø´Ü°ú °ü·ÃµÈ À±¸®Àû ¹× ¹ýÀû ¹®Á¦ ¼ºÀåÀ» ¾ïÁ¦Çϰí ÀÖ½À´Ï´Ù.
°Ô´Ù°¡ ÀüÀå À¯Àüü ½ÃÄö½ÌÀÇ ¿ëµµ Áõ°¡, ´ë±Ô¸ð À¯Àüü ½ÃÄö½Ì ÇÁ·ÎÁ§Æ®¿¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿ø, ½ÅÈï±¹Àº ÀÌ ½ÃÀå¿¡¼ »ç¾÷À» Àü°³ÇÏ´Â ±â¾÷¿¡°Ô ¼ºÀå ±âȸ¸¦ °¡Á®¿Ã °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±ÔÁ¦ »óȲ¿¡¼ÀÇ ºÒÈ®½Ç¼º, Áß¼Ò±Ô¸ð ½ÇÇè½ÇÀÇ Á¦ÇÑµÈ Àü¹® Áö½Ä°ú ½ÃÄö½Ì ´É·Â, ½ÅÈï ±¹°¡ÀÇ ½ÃÄö½Ì Àü¹®°¡ ºÎÁ·, NGS ¼³Ä¡¿¡ ÇÊ¿äÇÑ °í¾×ÀÇ ¼³ºñ ÅõÀÚ°¡ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä °úÁ¦°¡µÇ¾ú½À´Ï´Ù.
º» º¸°í¼´Â 4³â°£(2021-2024³â) Á¦Ç° Æ÷Æ®Æú¸®¿À Á¦°ø, Áö¿ªÁ¤¼¼, ¾÷°è¸¦ ¼±µµÇÏ´Â ½ÃÀå ±â¾÷ÀÌ Ã¤¿ëÇÑ ÁÖ¿ä Àü·« Àü°³ÀÇ ±¤¹üÀ§ÇÑ Æò°¡¿¡ ±Ù°ÅÇÑ °æÀï ±¸µµ¸¦ Á¦°øÇÕ´Ï´Ù.ÀÇ ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå¿¡¼ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷Àº Illumina, Inc.(¹Ì±¹), Thermo Fisher Scientific, Inc.(¹Ì±¹), QIAGEN NV(³×´ú¶õµå), F. Hoffmann-La Roche Ltd.(½ºÀ§½º), PerkinElmer, Inc.(¹Ì±¹), Agilent Technologies, Inc.(¹Ì±¹), Pacific Biosciences of California Inc.(¹Ì±¹), Danaher Corporation(¹Ì±¹), Bio-Rad Laboratories, Inc.(¹Ì±¹), Oxford Nanopore Technologies Plc.(¿µ±¹), MGI Tech Co., Ltd.(Áß±¹), Beijing Genomics Institute(BGI)(Áß±¹)ÀÔ´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ Á¶»çÇÑ ¸ðµç Á¦°ø Á¦Ç° Áß ¼Ò¸ðǰ ºÎ¹®Àº ÃÑ À¯Àüü ½ÃÄö½Ì ½ÃÀå¿¡¼ 70.1% ÃʰúÀÇ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½Ã¾à ¹× Ç¥Àû ³óÃà ÇÁ·ÎÅäÄÝ ¹× °ü·Ã ¼Ò¸ðǰÀÇ Áö¼ÓÀûÀÎ Áøº¸, ±×¸®°í ÀÓ»ó ȯ°æ¿¡¼ ÀüÀå À¯Àüü ½ÃÄö½ÌÀÇ ÀÀ¿ë Áõ°¡·Î ÀÎÇÑ °ÍÀ¸·Î °£Áֵ˴ϴÙ.
ÀÌ º¸°í¼¿¡¼ Á¶»çÇÑ ¸ðµç ½ÃÄö½Ì À¯Çü Áß¿¡¼ 2024³â¿¡´Â ÀüÀå À¯Àüü ½ÃÄö½Ì ºÎ¹®ÀÌ ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àüü ±Ô¸ðÀÇ À¯Àüü ½ÃÄö½ÌÀº À¯ÀüüÀÇ °íÇØ»óµµ¿Í ¿°±âº° ºä¸¦ Á¦°øÇϰí Áý´Ü ¼öÁØÀÇ ¿¬±¸¸¦ Á¦°øÇÏ´Â ´ë±Ô¸ð À¯Àüü ½ÃÄö½Ì¿¡ µµ¿òÀ̵DZ⠶§¹®ÀÔ´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ Á¶»çÇÑ ¸ðµç ±â¼ú Áß¿¡¼ 2024³â¿¡´Â ÇÕ¼º¿¡ ÀÇÇÑ ½ÃÄö½Ì ºÎ¹®ÀÌ ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå¿¡¼ ÃÖ´ëÀÇ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Æä¾î ¿£µå ¶óÀ̺귯¸®¿Í ½Ì±Û ·¹µå ¶óÀ̺귯¸®¸¦ ¸ðµÎ Áö¿øÇÏ°í °íÇØ»óµµ À¯Àüü ½ÃÄö½Ì¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ÇÕ¼º¿¡ ÀÇÇÑ ½ÃÄö½Ì ±â¼úÀÌ ³Î¸® ä¿ëµÇ°í Àֱ⠶§¹®À¸·Î »ý°¢µË´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ Á¶»çÇÑ ¸ðµç ¿ëµµ Áß¿¡¼ 2024³â¿¡´Â ¿¬±¸ ¿ëµµ ºÐ¾ß°¡ ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå¿¡¼ ÃÖ´ëÀÇ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½Å±Ô â¾à Ÿ°ÙÀÇ µ¿Á¤¿¡ ÀüÀå À¯Àüü ½ÃÄö½ÌÀÌ »ç¿ëµÇ°í ÀÖ´Â °Í, À¯ÀüÀÚ ±â¹ÝÀÇ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ´Â °Í, ÀǾàǰ ¿¬±¸°³¹ß Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ´Â °Í¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ Á¶»çÇÑ ¸ðµç ÃÖÁ¾ »ç¿ëÀÚ Áß¿¡¼ 2024³â¿¡´Â Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ ºÎ¹®ÀÌ ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¦¾à±â¾÷ ¹× »ý¸í°øÇбâ¾÷¿¡ ÀÇÇÑ ¿¬±¸°³¹ßºñ Áõ°¡¿Í ÀÌ·¯ÇÑ ¾÷°è¿¡¼ ÀüÀå À¯Àüü ½ÃÄö½ÌÀÇ Ã¤¿ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ´Â À¯Àü¼º ÁúȯÀÇ ÀÌȯÀ²ÀÇ »ó½Â¿¡ ÀÇÇÑ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼°èÀÇ ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀåÀÇ Áö¿ªº° ½Ã³ª¸®¿ÀÀÇ »ó¼¼ ºÐ¼®¿¡¼´Â 5°³ÀÇ ÁÖ¿ä Áö¿ª(ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿, ¾ÆÇÁ¸®Ä«)ÀÇ »ó¼¼ÇÑ Á¤¼ºÀû¡¤Á¤·®Àû µ¿ 2024³â¿¡´Â ºÏ¹Ì°¡ ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå¿¡¼ 52.1% ÀÌ»óÀÇ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. 2024³â ÀÌ Áö¿ª¿¡¼´Â ¹Ì±¹ÀÌ ºÏ¹ÌÀÇ ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê, NGS ±â¹Ý ¿¬±¸ ¿ëµµ Áõ°¡, ½ÃÄö½Ì ºñ¿ëÀÇ ÀúÇÏ, ¾ÏÀÇ ³ôÀº À¯º´·ü, Áö¿øÀûÀÎ »óȯ ½Ã³ª¸®¿À µîÀÇ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù.
ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå Æò°¡: Á¦°ø Á¦Ç°º°
Âü°í: ±âŸ ¼Ò¸ðǰ¿¡´Â ¹ÙÀ̾Ë, ÇÇÆê, ¿ë±â, Æ®·¹ÀÌ, ½ÃÄö½Ì ½Ã¾à, ÇÃ·Î¿ì ¼¿, Æ©ºê µîÀÌ Æ÷ÇԵ˴ϴÙ.
ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå Æò°¡: ½ÃÄö½Ì À¯Çüº°
Âü°í: ±âŸ Ȧ À¯Àüü ½ÃÄö½Ì À¯Çü¿¡´Â µ¥³ëº¸ ½ÃÄö½Ì, À§»ó ½ÃÄö½Ì, ±ä ¸®µå ½ÃÄö½Ì, Ŭ·Ð ¹ÙÀÌŬ·Ð ½ÃÄö½Ì°¡ Æ÷ÇԵ˴ϴÙ.
ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå Æò°¡: ±â¼úº°
Âü°í: ±âŸ ÀüÀå À¯Àüü ½ÃÄö½Ì ±â¼ú¿¡´Â ³ª³ëÆ÷¾î ½ÃÄö½Ì, AVITI ½ÃÄö½Ì(Avidity base chemistry(ABC))°¡ Æ÷ÇԵ˴ϴÙ.
ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå Æò°¡: ¿ëµµº°
Âü°í: ±âŸ ¿ëµµ·Î´Â ½Äǰ ¹Ì»ý¹°ÇÐ, À½·á »ê¾÷¿¡¼ ¹Ì»ý¹°ÃÑ ºÐ¼®, ȯ°æ Á¶»ç µîÀÌ Æ÷ÇԵ˴ϴÙ.
±âŸ ÀÓ»ó ¿ëµµ·Î´Â ½Å°æÁúȯ, Èñ±ÍÁúȯ, ´ë»ç¡¤¸é¿ªÁúȯ, ½Äǰ¸Å°³Áúȯ¿¡¼ÀÇ À¯ÀüÀÚÀÌ»óÀÇ °ËÃâÀÌ Æ÷ÇԵ˴ϴÙ.
ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå Æò°¡ <: ÃÖÁ¾ »ç¿ëÀÚº°/p>
Âü°í: ±âŸ ÃÖÁ¾ »ç¿ëÀÚ´Â ÁÖ·Î ¹ýÀÇÇÐ ¿¬±¸¼Ò, º¸¾È ±â°ü, ½Äǰ ¹× À½·á ȸ»ç ¹× ³ó¾÷ ȸ»ç¸¦ Æ÷ÇÔÇÕ´Ï´Ù.
ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå Æò°¡: Áö¿ªº°
(Âü°í: »óÀ§ 5°³»çÀÇ SWOT ºÐ¼® Á¦°ø)
The global whole genome sequencing market is projected to reach $7.17 billion by 2031 at a CAGR of 15.2% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the spirometers market is driven by the declining costs of sequencing, the increasing prevalence of cancer & genetic disorders, the growing utilization of whole genome sequencing in disease diagnostics & precision medicine, increasing pharmaceutical R&D expenditures, improvements in regulatory & reimbursement scenarios for whole genome sequencing, rising healthcare expenditures, increasing funding for research activities, the growing need for the early detection & prevention of diseases, technological advancements in sequencing products, and government initiatives promoting the use of sequencing in clinical & research applications. However, the high costs of whole genome sequencing consumables, the low chances of identifying positive, actionable mutations for precision medicine, and the ethical & legal issues related to whole genome sequencing-based diagnosis restrain the growth of this market.
Furthermore, increasing applications of whole genome sequencing, government support for large-scale genomic sequencing projects, and emerging economies are expected to generate growth opportunities for the players operating in this market. However, the uncertainties in the regulatory landscape, the limited expertise & sequencing capabilities of small & medium-sized laboratories, the lack of sequencing professionals in developing countries, and the high capital investments required for NGS setups pose a major challenge to market growth.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2021-2024). The key players operating in the global whole genome sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S) Agilent Technologies, Inc. (U.S), Pacific Biosciences of California Inc. (U.S), Danaher Corporation (U.S), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K),MGI Tech Co., Ltd. (China), Beijing Genomics Institute (BGI) (China).
Among all the offerings studied in this report, the consumables segment is expected to account for the largest share of over 70.1% of the whole genome sequencing market. This segment's large market share can be attributed to the recurring use of consumables, continuous advancements in reagents and target enrichment protocols and associated consumables, and the increasing applications of whole genome sequencing in clinical settings.
Among all the sequencing types studied in this report, in 2024, the whole genome sequencing segment is expected to account for the largest share of the whole genome sequencing market. This segment's large market share can be attributed to the large whole genome sequencing provides high resolution and base-by-base view of the genome and helps in sequencing large genome for providing population-level studies.
Among all the technologies studied in this report, in 2024, the sequencing by synthesis segment is expected to account for the largest share of the whole genome sequencing market. This segment's large market share can be attributed to the widespread adoption of sequencing by synthesis technology, which offers high accuracy and supports both paired-end and single-read libraries, enabling high-resolution genome sequencing.
Among all the applications studied in this report, in 2024, the research applications segment is expected to account for the largest share of the whole genome sequencing market. This segment's large market share is attributed to the increasing use of whole genome sequencing to identify novel drug targets, the rising demand for gene-based medicines, and growing investments in drug research and development activities.
Among all the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the whole genome sequencing market. This segment's large market share can be attributed to increased R&D spending by pharmaceutical and biotechnology firms, along with the rising incidence of genetic diseases, which is fueling the adoption of whole genome sequencing in these industries.
An in-depth analysis of the geographical scenario of the global whole genome sequencing market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of over 52.1% of the whole genome sequencing market. In the region in 2024, the U.S. is expected to account for the largest share of the whole genome sequencing market in North America. North America's significant market share can be attributed to factors such as high awareness of whole genome sequencing, favorable government initiatives supporting genomics research, increasing applications of NGS-based research, decreasing sequencing costs, a high prevalence of cancer, and a supportive reimbursement scenario.
Whole Genome Sequencing Market Assessment- by Offering
Note: Other consumables include vials, pipettes, containers, trays, sequencing reagents, flow cells, and tubes.
Whole Genome Sequencing Market Assessment- by Sequencing Type
Note: Other Whole-genome sequencing types include De novo sequencing, Phased sequencing, Long-read sequencing, and Clone-by-clone sequencing.
Whole Genome Sequencing Market Assessment- by Technology
Note: Other whole genome sequencing technologies include nanopore sequencing and AVITI sequencing (Avidity base chemistry (ABC).
Whole Genome Sequencing Market Assessment-by Application
Note: Other applications include food microbiology, microbiota analysis in the beverage industry, and environmental studies.
Other clinical applications include the detection of genetic aberrations in neurological disorders, rare diseases, metabolic and immune disorders, and food-borne illnesses.
Whole Genome Sequencing Market Assessment-by End User
Note: Other end users primarily include forensic laboratories & security agencies, food & beverage companies, and agriculture companies.
Whole Genome Sequencing Market Assessment-by Geography
(Note: SWOT analyses of the top 5 companies will be provided.)